# C-Ray Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/c-ray-therapeutics

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.c-raytherapeutics.com
- Total disclosed funding: $106M
- Latest round: Series A (Nov 16, 2024)
- Investors on record: 6

## About

Founded in 2021 and based in Chengdu, China, C-Ray Therapeutics operates as a pharmaceutical company that focuses on the development and production of radiopharmaceuticals. Tongrui Biopharmaceutical (Shanghai) Co., Ltd is the branch office of the company. It also has another branch in Beijing. The company has applied for 15 patents. It cooperated with Tongyi Pharmaceutical, Tongrun Bio, and other companies. In June 2023, the company's Zhangjiang R&D laboratory was put into use. In November 2024, C-Ray Therapeutics raised a series A+ funding for over USD 100 million.

C-Ray Therapeutics engages in the research, development, production, clinical application, and commercialization of radiopharmaceuticals. Its related products have been officially approved by the US FDA for clinical treatment. The company provides molecular imaging CRO and companion diagnostic development services, verification services for the drugability of new drugs developed for innovative targets, CRDMO services, etc.

The company generates revenue by providing radiopharmaceuticals.

The company will use the series A+ funding for the improvement of targeted precursor discovery platforms, RDC's high-throughput drug screening capabilities upgrade, and research and development of drug and product pipelines.

## Funding rounds

- Series A, Nov 16, 2024, $100M — 3SBio Inc., Shenzhen Capital Real Estate Fund, GL Ventures, Tailong VC, Geuniom Group
- Series A, Aug 5, 2022, $4M — HBM Partners
- Series A, Jul 30, 2021, $2M — HBM Partners

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- 3SBio Inc. — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A
- Geuniom Group — Series A